✦ LIBER ✦

A one-year study to assess the safety and efficacy of the CB1R inverse agonist taranabant in overweight and obese patients with type 2 diabetes

✍ Scribed by M. S. Kipnes; P. Hollander; K. Fujioka; I. Gantz; T. Seck; N. Erondu; Y. Shentu; K. Lu; S. Suryawanshi; M. Chou; A. O. Johnson-Levonas; S. B. Heymsfield; D. Shapiro; K. D. Kaufman; J. M. Amatruda

Book ID: 109044945
Publisher: John Wiley and Sons
Year: 2010
Tongue: English
Weight: 687 KB
Volume: 12
Category: Article
ISSN: 1462-8902
DOI: 10.1111/j.1463-1326.2009.01188.x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Efficacy and safety of sitagliptin when

Efficacy and safety of sitagliptin when added to ongoing metformin therapy in patients with type 2 diabetes

✍ R. Scott; T. Loeys; M. J. Davies; S. S. Engel; for the Sitagliptin Study 801 Gro 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 178 KB

Efficacy and safety of the PPARγ partial

Efficacy and safety of the PPARγ partial agonist balaglitazone compared with pioglitazone and placebo: a phase III, randomized, parallel-group study in patients with type 2 diabetes on stable insulin therapy

✍ Kim Henriksen; Inger Byrjalsen; Per Qvist; Henning Beck-Nielsen; Gitte Hansen; B 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 357 KB 👁 1 views

## Abstract ## Background Treatment of patients with perioxisome proliferator‐activated receptor‐γ full agonists are associated with weight gain, heart failure, peripheral oedema, and bone loss. However, the safety of partial perioxisome proliferator‐activated receptor‐γ agonists has not been esta

The effects of LY2189265, a long-acting

The effects of LY2189265, a long-acting glucagon-like peptide-1 analogue, in a randomized, placebo-controlled, double-blind study of overweight/obese patients with type 2 diabetes: the EGO study

✍ G. E. Umpierrez; T. Blevins; J. Rosenstock; C. Cheng; J. H. Anderson; E. J. Bast 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 652 KB

Efficacy and safety of the dipeptidyl pe

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double-blind, non-inferiority trial

✍ M. A. Nauck; G. Meininger; D. Sheng; L. Terranella; P. P. Stein; Sitagliptin Stu 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 191 KB